17:00 Thu 07 May 2020
ReNeuron Group plc - CTX cell line shows further potential
7 May 2020 | AIM: RENE |
ReNeuron Group plc
("
Newly published positive efficacy data in an accepted model of Huntington's disease
The new data show for the first time that
This study was led by Professor
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.3191
The Company has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic injury. The new data being published today show that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.
These results are particularly encouraging as they also demonstrate that CTX, a well-characterised neural stem cell line that has been evaluated in multiple pre-clinical and clinical studies, can differentiate into medium spiny neurons, engraft into host tissue and form functional connections with the surrounding tissue.
The Company believes that these new positive data will add further value to its CTX cell therapy candidate in the context of future out-licensing deals with development partners in due course.
Dr
"The data being published today represent a significant advance in the potential use of human allogeneic stem cell lines as therapeutic candidates for the treatment of Huntington's disease. Importantly, the immortalisation technology found within
ENDS
ENQUIRIES:
|
+44 (0) 20 3819 8400 | | |
| | | |
| | | |
Buchanan ( |
+44 (0) 20 7466 5000 | | |
Mark Court, | | | |
|
+1 212 600 1902 | | |
| | | |
| +44 (0) 20 7710 7600
| | |
N+1 Singer (Joint Broker) |
+44 (0) 20 7496 3000 | | |
About
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE